Clinical trials in Langenau – page 5

649 clinical trials in Langenau, Germany across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in GermanyKlinischeStudien.de

Langenau at a glance

649

clinical trials

Research sites1

Quick filters

649 trials in Langenau

Open in trial search

Gastric cancer+2

Recruiting

A study of pumitamig and a drug combination versus nivolumab and a drug combination for patients with untreated advanced or metastatic stomach or esophageal cancer

Registered drugNo placebo

A study of pumitamig and a drug combination versus nivolumab and a drug combination for patients with untreated advanced or metastatic stomach or esophageal cancer

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Calcium Folinate
Sponsor:Bristol-Myers Squibb Services Unlimited Company

Contact Research Centre

Clear cell renal cell carcinoma

Recruiting

A Study Testing Casdatifan and Cabozantinib Compared to Placebo and Cabozantinib in Patients With Advanced Clear Cell Kidney Cancer

Registered drug

A Study Testing Casdatifan and Cabozantinib Compared to Placebo and Cabozantinib in Patients With Advanced Clear Cell Kidney Cancer

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:AB521
Sponsor:Arcus Biosciences Inc.

Contact Research Centre

Non-small cell lung cancer stage IV+2

Recruiting

A Study of BMS-986504 with Drug Combination Compared to Placebo with Drug Combination in Patients with Advanced Non-Small Cell Lung Cancer Starting First Treatment

Registered drug

A Study of BMS-986504 with Drug Combination Compared to Placebo with Drug Combination in Patients with Advanced Non-Small Cell Lung Cancer Starting First Treatment

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Bristol-Myers Squibb Services Unlimited Company

Contact Research Centre

Actinic keratosis

Recruiting

Study on the Effectiveness of Green Tea Leaf Extract Ointment for Adults with Actinic Keratosis on the Scalp and Face

Registered drug

Study on the Effectiveness of Green Tea Leaf Extract Ointment for Adults with Actinic Keratosis on the Scalp and Face

Registered drug

Germany

Participants:18–64 years · 65+ years
Sponsor:Aresus Pharma GmbH

Contact Research Centre

Huntington's disease

Recruiting

Phase 3 Study of Pridopidine Hydrochloride for Safety and Efficacy in Adults with Huntington’s Disease

Investigational

Phase 3 Study of Pridopidine Hydrochloride for Safety and Efficacy in Adults with Huntington’s Disease

Investigational

Germany

Participants:18–64 years · 65+ years
Substances:Pridopidine hydrochloride
Sponsor:Ferrer Internacional S.A.

Contact Research Centre

Type 1 diabetes mellitus

Recruiting

A Study of Baricitinib to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes

Registered drug

A Study of Baricitinib to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes

Registered drug

Germany

Participants:0–17 years · 18–64 years
Substances:Baricitinib
Sponsor:Eli Lilly & Co.

Contact Research Centre

DNAJB1-PRKACA trifluoracetate peptide vaccine and atezolizumab in patients with fibrolamellar hepatocellular carcinoma and other DNAJB1-PRKACA fusion tumors

Recruiting

Registered drugNo placebo

DNAJB1-PRKACA trifluoracetate peptide vaccine and atezolizumab in patients with fibrolamellar hepatocellular carcinoma and other DNAJB1-PRKACA fusion tumors

Registered drugNo placebo

Germany

Participants:0–17 years · 18–64 years · 65+ years
Substances:Atezolizumab
Sponsor:Universitaetsklinikum Tuebingen AöR

Contact Research Centre

Transitional cell carcinoma

Recruiting

Adjuvant Datopotamab Deruxtecan with Drug Combination in Patients with High‑Risk Muscle‑Invasive Urothelial Carcinoma

Registered drugNo placebo

Adjuvant Datopotamab Deruxtecan with Drug Combination in Patients with High‑Risk Muscle‑Invasive Urothelial Carcinoma

Registered drugNo placebo

Germany

Participants:18–64 years
Substances:Durvalumab
Sponsor:AstraZeneca AB

Contact Research Centre

Crohn's disease

Recruiting

Efficacy and safety of ontunisertib in patients with fibrostenosing Crohn’s disease: a phase 2b randomized, double‑blind, placebo‑controlled dose‑ranging trial

Investigational

Efficacy and safety of ontunisertib in patients with fibrostenosing Crohn’s disease: a phase 2b randomized, double‑blind, placebo‑controlled dose‑ranging trial

Investigational

Germany

Participants:18–64 years · 65+ years
Substances:ORG-129
Sponsor:Agomab Spain S.L.U.

Contact Research Centre

Chronic graft versus host disease

Recruiting

Study of belumosudil versus drug combination in patients aged 12 years and older with chronic graft‑versus‑host disease refractory after prior therapy

Registered drugNo placebo

Study of belumosudil versus drug combination in patients aged 12 years and older with chronic graft‑versus‑host disease refractory after prior therapy

Registered drugNo placebo

Germany

Participants:0–17 years · 18–64 years · 65+ years
Substances:Belumosudil
Sponsor:Sanofi-Aventis Recherche & Developpement

Contact Research Centre

Adenocarcinoma pancreas

Recruiting

First‑line Study of RMC‑9805 with Investigator’s Choice Chemotherapy Drug Combination vs Chemotherapy Alone in Patients with Metastatic KRAS G12D‑Mutated Pancreatic Adenocarcinoma

Investigational

First‑line Study of RMC‑9805 with Investigator’s Choice Chemotherapy Drug Combination vs Chemotherapy Alone in Patients with Metastatic KRAS G12D‑Mutated Pancreatic Adenocarcinoma

Investigational

Germany

Participants:18–64 years · 65+ years
Sponsor:Revolution Medicines Inc.

Contact Research Centre

Polycythaemia vera

Recruiting

A Phase 3 Study of Sapablursen Compared with Placebo in Adults with Polycythemia Vera

Investigational

A Phase 3 Study of Sapablursen Compared with Placebo in Adults with Polycythemia Vera

Investigational

Germany

Participants:18–64 years · 65+ years
Substances:Sapablursen
Sponsor:Deciphera Pharmaceuticals Inc.

Contact Research Centre

Other cities in Germany

The busiest research cities in the country

All 504 cities in Germany

Clinical research in Langenau

What the registry says about research in the country

01 Inflammatory Skin Conditions

Clinical research focusing on plaque psoriasis and psoriatic arthritis, evaluating novel therapeutic approaches for both biologic-naive and experienced patients. Studies aim to assess treatment efficacy in reducing disease symptoms and improving patient outcomes.

Moderate to Severe Plaque Psoriasis
Active Psoriatic Arthritis
Long-term Safety Studies

Multiple investigations are comparing new therapeutic agents against placebo and established treatments.

02 Chronic Skin Disorders

Comprehensive studies addressing hidradenitis suppurativa and atopic dermatitis. Research focuses on evaluating new treatments for these challenging conditions, with emphasis on both immediate efficacy and long-term management.

Hidradenitis Suppurativa Management
Atopic Dermatitis Treatments
Novel Therapeutic Approaches

Trials are examining both topical and systemic treatments for optimal disease control.

03 Dermatological Conditions

Innovative research addressing various skin conditions including chronic venous ulcers, actinic keratosis, and rosacea. Studies range from stem cell therapies for wound healing to novel topical treatments.

Wound Healing Therapies
Skin Lesion Treatments
Inflammatory Conditions

Research includes both traditional and cutting-edge therapeutic approaches.

Back to Germany All countries